vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and GCM Grosvenor Inc. (GCMG). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $177.1M, roughly 1.4× GCM Grosvenor Inc.). GCM Grosvenor Inc. runs the higher net margin — 32.8% vs 11.1%, a 21.7% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 7.2%). GCM Grosvenor Inc. produced more free cash flow last quarter ($175.0M vs $29.1M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 27.5%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
GCM Grosvenor is an American alternative asset management firm, with approximately $76 billion in assets under management and approximately 530 professionals as of 2023.
ANIP vs GCMG — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $177.1M |
| Net Profit | $27.5M | $58.2M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | 30.9% |
| Net Margin | 11.1% | 32.8% |
| Revenue YoY | 29.6% | 7.2% |
| Net Profit YoY | 367.5% | 149.2% |
| EPS (diluted) | $1.14 | $0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $177.1M | ||
| Q3 25 | $227.8M | $135.0M | ||
| Q2 25 | $211.4M | $119.7M | ||
| Q1 25 | $197.1M | $125.8M | ||
| Q4 24 | $190.6M | $165.3M | ||
| Q3 24 | $148.3M | $122.9M | ||
| Q2 24 | $138.0M | $117.0M | ||
| Q1 24 | $137.4M | $108.9M |
| Q4 25 | $27.5M | $58.2M | ||
| Q3 25 | $26.6M | $10.5M | ||
| Q2 25 | $8.5M | $15.4M | ||
| Q1 25 | $15.7M | $463.0K | ||
| Q4 24 | $-10.3M | $7.6M | ||
| Q3 24 | $-24.2M | $4.2M | ||
| Q2 24 | $-2.3M | $4.8M | ||
| Q1 24 | $18.2M | $2.1M |
| Q4 25 | 14.1% | 30.9% | ||
| Q3 25 | 15.9% | 32.7% | ||
| Q2 25 | 6.6% | 16.1% | ||
| Q1 25 | 13.3% | 12.2% | ||
| Q4 24 | -2.3% | 26.4% | ||
| Q3 24 | -13.8% | 20.3% | ||
| Q2 24 | 3.7% | 17.8% | ||
| Q1 24 | 14.8% | -14.7% |
| Q4 25 | 11.1% | 32.8% | ||
| Q3 25 | 11.7% | 7.8% | ||
| Q2 25 | 4.0% | 12.9% | ||
| Q1 25 | 8.0% | 0.4% | ||
| Q4 24 | -5.4% | 4.6% | ||
| Q3 24 | -16.3% | 3.4% | ||
| Q2 24 | -1.7% | 4.1% | ||
| Q1 24 | 13.2% | 2.0% |
| Q4 25 | $1.14 | $0.23 | ||
| Q3 25 | $1.13 | $0.16 | ||
| Q2 25 | $0.36 | $0.05 | ||
| Q1 25 | $0.69 | $-0.02 | ||
| Q4 24 | $-0.45 | $0.09 | ||
| Q3 24 | $-1.27 | $0.03 | ||
| Q2 24 | $-0.14 | $0.04 | ||
| Q1 24 | $0.82 | $-0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $242.1M |
| Total DebtLower is stronger | — | $428.4M |
| Stockholders' EquityBook value | $540.7M | $27.0M |
| Total Assets | $1.4B | $813.8M |
| Debt / EquityLower = less leverage | — | 15.87× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $242.1M | ||
| Q3 25 | $262.6M | $182.7M | ||
| Q2 25 | $217.8M | $136.3M | ||
| Q1 25 | $149.8M | $94.5M | ||
| Q4 24 | $144.9M | $89.5M | ||
| Q3 24 | $145.0M | $98.4M | ||
| Q2 24 | $240.1M | $73.9M | ||
| Q1 24 | $228.6M | $41.9M |
| Q4 25 | — | $428.4M | ||
| Q3 25 | — | $429.3M | ||
| Q2 25 | — | $430.2M | ||
| Q1 25 | — | $431.1M | ||
| Q4 24 | — | $432.0M | ||
| Q3 24 | — | $432.9M | ||
| Q2 24 | — | $433.8M | ||
| Q1 24 | — | $384.0M |
| Q4 25 | $540.7M | $27.0M | ||
| Q3 25 | $505.8M | $-7.4M | ||
| Q2 25 | $436.8M | $-12.3M | ||
| Q1 25 | $418.6M | $-28.3M | ||
| Q4 24 | $403.7M | $-27.6M | ||
| Q3 24 | $405.9M | $-31.9M | ||
| Q2 24 | $455.8M | $-28.5M | ||
| Q1 24 | $452.0M | $-26.4M |
| Q4 25 | $1.4B | $813.8M | ||
| Q3 25 | $1.4B | $685.9M | ||
| Q2 25 | $1.3B | $636.9M | ||
| Q1 25 | $1.3B | $579.8M | ||
| Q4 24 | $1.3B | $612.7M | ||
| Q3 24 | $1.3B | $575.0M | ||
| Q2 24 | $920.8M | $543.9M | ||
| Q1 24 | $914.5M | $497.3M |
| Q4 25 | — | 15.87× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $183.5M |
| Free Cash FlowOCF − Capex | $29.1M | $175.0M |
| FCF MarginFCF / Revenue | 11.8% | 98.8% |
| Capex IntensityCapex / Revenue | 0.5% | 4.8% |
| Cash ConversionOCF / Net Profit | 1.10× | 3.16× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $326.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $183.5M | ||
| Q3 25 | $44.1M | $79.8M | ||
| Q2 25 | $75.8M | $42.0M | ||
| Q1 25 | $35.0M | $33.3M | ||
| Q4 24 | $15.9M | $148.8M | ||
| Q3 24 | $12.5M | $69.0M | ||
| Q2 24 | $17.4M | $17.5M | ||
| Q1 24 | $18.3M | $24.2M |
| Q4 25 | $29.1M | $175.0M | ||
| Q3 25 | $38.0M | $78.3M | ||
| Q2 25 | $71.8M | $40.8M | ||
| Q1 25 | $32.5M | $32.1M | ||
| Q4 24 | $13.5M | $132.0M | ||
| Q3 24 | $7.7M | $62.2M | ||
| Q2 24 | $13.0M | $12.8M | ||
| Q1 24 | $13.7M | $20.0M |
| Q4 25 | 11.8% | 98.8% | ||
| Q3 25 | 16.7% | 58.0% | ||
| Q2 25 | 34.0% | 34.1% | ||
| Q1 25 | 16.5% | 25.5% | ||
| Q4 24 | 7.1% | 79.9% | ||
| Q3 24 | 5.2% | 50.6% | ||
| Q2 24 | 9.4% | 10.9% | ||
| Q1 24 | 10.0% | 18.4% |
| Q4 25 | 0.5% | 4.8% | ||
| Q3 25 | 2.7% | 1.1% | ||
| Q2 25 | 1.9% | 1.0% | ||
| Q1 25 | 1.3% | 0.9% | ||
| Q4 24 | 1.3% | 10.1% | ||
| Q3 24 | 3.2% | 5.5% | ||
| Q2 24 | 3.2% | 4.0% | ||
| Q1 24 | 3.3% | 3.9% |
| Q4 25 | 1.10× | 3.16× | ||
| Q3 25 | 1.66× | 7.61× | ||
| Q2 25 | 8.87× | 2.72× | ||
| Q1 25 | 2.23× | 71.84× | ||
| Q4 24 | — | 19.54× | ||
| Q3 24 | — | 16.60× | ||
| Q2 24 | — | 3.64× | ||
| Q1 24 | 1.00× | 11.40× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
GCMG
| Asset Management1 | $108.6M | 61% |
| Management Service Incentive Performance Fees | $61.7M | 35% |
| Management Service Incentive Carried Interest | $5.1M | 3% |
| Service Other | $1.8M | 1% |
